Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

• Status: Terminated
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Archemix Corp.

Criteria

Inclusion Criteria:

• Male or female;

• ≥18 to ≤75 years of age;

• Diagnosis of TMA based on presence of:

• Thrombocytopenia, defined as a platelet count <100 x 109 per liter;

• Microangiopathic hemolytic anemia, defined by negative findings on direct antiglobulin test, and evidence of accelerated red blood cell (RBC) production and destruction); AND

• Absence of a clinically apparent alternative explanation for thrombocytopenia and anemia, e.g., disseminated intravascular coagulation (DIC), eclampsia, HELLP syndrome, Evans syndrome;

• Females: non-pregnant and commit to use of effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment;

• Males: commit to use of a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment;

• Not received an unlicensed investigational agent (drug, device, or blood-derived product) within 30 days prior to randomization, and may not receive such an investigational agent in the 30 days post-randomization (note: investigational use for treatment of TMA of a licensed immunomodulator, e.g., rituximab, is permitted at any time relative to randomization);

• Capable of understanding and complying with the protocol, and he/she (or a legal representative) must have signed the informed consent document prior to performance of any study-related procedures.

Patients who have again become acutely ill following recent treatment and achievement of a brief remission of acute TMA may be enrolled in the study if ALL of the following conditions are met:

• Disease activity in the patient in unabated (e.g. persistent thrombocytopenia and microangiopathic hemolytic anemia with ongoing neurological symptoms and/or troponin elevation);

• The last plasma exchange of the patient's preceding course of treatment occurred at least 7 days prior;

• The patient did not undergo splenectomy during the preceding course of treatment;

• The new course of plasma exchange has not been ongoing for more than 3 days.

Exclusion Criteria:

• Females: pregnant or <24 hours post-partum, or breastfeeding;

• History of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days;

• Disseminated malignancy or other co-morbid illness limiting life expectancy to ≤3 months independent of the TMA disorder.

• Diagnosis other than TMA which can account for the findings of thrombocytopenia and hemolytic anemia (e.g., DIC, HELLP syndrome, Evans syndrome);

• Diagnosis of DIC verified by laboratory values for D-dimer, fibrinogen, prothrombin time (PT), and activated partial thromboplastin time (aPTT).

Patients who have again become acutely ill following recent treatment and achievement of a brief remission of acute TMA may not be enrolled in the study if ANY of the following conditions are met:

• The last plasma exchange of the patient's preceding course of treatment occurred less than 7 days prior;

• The patient underwent splenectomy during the preceding course of treatment;

• The new course of plasma exchange has been ongoing for more than 3 days.